Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

The study found that weight regain varied with follow-up, with participants experiencing weight regain at eight, 12, and 20 ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

As anyone who prescribes GLP-1 therapies is surely aware, access remains a significant barrier to treatment due to lack of insurance coverage and, at times, lack of medication supply. In these ...

Men receiving tirzepatide showed greater reductions in body weight and waist circumference and improvements in erectile ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.